Want to see CGEN full AI Analyst Report?
Top Page
Compugen
(NASDAQ:CGEN)
Select Model
Select Model
Rating:70Outperform
Price Target:
$2.50
▲(9.65% Upside)
Action:Upgraded
Date:08/04/26
The score is driven primarily by improved financial performance (2025 profitability/cash generation and low leverage), tempered by concerns about sustainability given prior multi-year losses and cash burn. Technicals are neutral-to-slightly positive, valuation is supported by a low P/E, and the earnings call adds cautious optimism via runway and partnership upside but with material clinical/regulatory and partner-dependence risks.
Positive Factors
Cash runway and low leverage
A debt-free balance sheet and cash runway into 2029 give Compugen time to advance clinical programs without near-term financing pressure, reducing dilution risk and supporting sustained investment in its immuno-oncology pipeline.
Negative Factors
MAIA has limited regulatory and statistical weight
The small, exploratory design may limit the regulatory significance of the interim readout and could require follow-up studies before approval. That increases development time, funding needs and uncertainty around the commercial value of COM701.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway and low leverage
A debt-free balance sheet and cash runway into 2029 give Compugen time to advance clinical programs without near-term financing pressure, reducing dilution risk and supporting sustained investment in its immuno-oncology pipeline.
Read all positive factors
Compugen (CGEN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$225.04M
Dividend YieldN/A
Average Volume (3M)258.05K
Price to Earnings (P/E)6.5
Beta (1Y)1.53
Revenue Growth234.18%
EPS GrowthN/A
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.38
Shares Outstanding94,553,190
10 Day Avg. Volume221,395
30 Day Avg. Volume258,049
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.39
Price to Sales (P/S)1.96
P/FCF Ratio4.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.00Price Target Upside119.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$9.68M
Compugen Business Overview & Revenue Model
Company Description
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across...
How the Company Makes Money
Compugen primarily makes money through collaboration and licensing arrangements with larger biopharmaceutical companies and, to the extent applicable, related R&D funding and payments tied to partnered programs. Under these types of agreements, re...
Compugen Earnings Call Summary
Earnings Call Date:Aug 03, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call conveyed measurable progress across Compugen's pipeline and partnerships — notable trial milestones (MAIA interim due Q1 2027), encouraging partner data (rilvegostomig ASCO OS signal), strengthened cash runway into 2029, and material milestone/royalty upside from Gilead and AstraZeneca. Offsetting these positives are key uncertainties: MAIA's exploratory design and lowered control-arm PFS benchmark, absence of pre-readout FDA engagement, early-stage status and limited visibility for GS-0321 data, dependency on partner execution for value realization, and continued modest absolute revenues with ongoing net losses. Overall, the fundamentals improved and near-term clinical and financial visibility increased, but meaningful regulatory and partner-driven milestones remain future-dependent.Positive Updates
MAIA-ovarian Progress and Upcoming Interim Analysis
MAIA-ovarian (COM701 monotherapy) continuing on track for interim analysis by Q1 2027; trial is randomized with ~40 patients on COM701 vs ~20 placebo, and clinically meaningful success defined as PFS ≥ 6 months.
Negative Updates
MAIA Control Arm Benchmark Revised Downward
Based on two recent European trials (TEDOVA and OReO) the company revised its estimate for the MAIA placebo control median PFS to ~4 months versus historical PARP registration benchmarks (~5.5 months) — a reduction of ~1.5 months (~27% decrease) — introducing uncertainty around baseline assumptions.
Read all updates
Q2-2026 Updates
Positive
Negative
MAIA-ovarian Progress and Upcoming Interim Analysis
MAIA-ovarian (COM701 monotherapy) continuing on track for interim analysis by Q1 2027; trial is randomized with ~40 patients on COM701 vs ~20 placebo, and clinically meaningful success defined as PFS ≥ 6 months.
Read all positive updates
Company Guidance
Management guided that the MAIA‑ovarian interim analysis (median PFS data) is expected by Q1 2027, estimating the blinded placebo control median PFS at ~4 months (citing recent European trial control arms at 2.8 months and historical PARP registration ~5.5 months) and defining clinically meaningful success as ≥6 months PFS; MAIA is an exploratory, placebo‑controlled randomized trial (COM701 monotherapy ~40 patients vs ~20 placebo) and is not powered as a registrational study. On the financial side, cash and equivalents were ~$125.3M as of June 30, 2026 with a cash runway into 2029 assuming no further inflows; Q2‑2026 revenue was ~$2.6M (vs ~$1.3M a year ago), R&D expense ~$6.3M (vs ~$5.6M), G&A ~$2.3M (vs ~$2.2M), and net loss ~ $7.0M or $0.07 per share (vs ~$7.3M or $0.08). Partnership and pipeline metrics highlighted include $90M received to date from Gilead for GS‑0321 (up to $758M additional milestones + single‑digit to low‑double‑digit royalties), AstraZeneca adding a 12th Phase III rilvegostomig trial and previously guiding a >$5B non‑risk‑adjusted peak‑year revenue potential (plus up to $195M in milestones and mid‑single‑digit tiered royalties), and AstraZeneca’s GEMINI hepatobiliary rilve combo showing 16.8 months OS versus historical <13 months.Compugen Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
82
Very Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.00M | 72.76M | 27.86M | 33.46M | 7.50M | 6.00M |
| Gross Profit | 64.30M | 63.51M | 19.93M | 31.45M | 6.53M | 5.32M |
| EBITDA | 35.24M | 35.87M | -9.19M | -9.28M | -33.13M | -33.72M |
| Net Income | 35.19M | 35.34M | -14.23M | -18.75M | -33.69M | -34.20M |
Balance Sheet | ||||||
| Total Assets | 138.37M | 156.87M | 115.00M | 121.33M | 94.18M | 132.16M |
| Cash, Cash Equivalents and Short-Term Investments | 125.30M | 145.64M | 103.25M | 50.69M | 83.35M | 117.05M |
| Total Debt | 3.02M | 2.96M | 2.91M | 1.35M | 1.93M | 2.75M |
| Total Liabilities | 49.63M | 54.14M | 60.08M | 55.77M | 16.50M | 25.47M |
| Stockholders Equity | 88.73M | 102.73M | 54.91M | 65.56M | 77.68M | 106.69M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 31.33M | 49.49M | -36.06M | -34.60M | -22.98M |
| Operating Cash Flow | 0.00 | 31.63M | 49.60M | -35.89M | -34.11M | -22.69M |
| Investing Cash Flow | 0.00 | 30.00M | -46.25M | 35.51M | 37.06M | 6.62M |
| Financing Cash Flow | 0.00 | 10.60M | 554.00K | 3.08M | 353.00K | 16.84M |
Compugen Technical Analysis
Positive
2.28
Price Trends
2.26
Positive
2.44
Negative
2.11
Positive
Market Momentum
0.03
Negative
55.16
Neutral
50.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEN, the sentiment is Positive. The current price of 2.28 is below the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.26, and above the 200-day MA of 2.11, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 50.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGEN.
Compugen Risk Analysis
Compugen disclosed 79 risk factors in its most recent earnings report. Compugen reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Compugen Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $225.04M | 6.50 | 42.57% | ― | 234.18% | ― | |
56 Neutral | $747.71M | -15.02 | -43.57% | ― | -66.63% | 57.89% | |
52 Neutral | $681.28M | -17.81 | -147.78% | ― | ― | -13.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $514.25M | -4.21 | -45.45% | ― | 2.33% | 36.86% | |
44 Neutral | $172.62M | -1.62 | -39.64% | ― | ― | -6.70% | |
44 Neutral | $81.74M | -1.47 | -1266.43% | ― | ― | 49.43% |
* Healthcare Sector Average
CGEN
Compugen
2.44
1.00
69.44%
NKTX
Nkarta
2.54
0.28
12.39%
CCCC
C4 Therapeutics
4.21
1.61
61.92%
STTK
Shattuck Labs
7.66
6.65
658.42%
ELTX
Elicio Therapeutics
3.13
-8.12
-72.18%
NVCT
Nuvectis Pharma
23.33
16.79
256.73%
Compugen Corporate Events
Compugen Sets September 10, 2026 Annual Meeting, Details Board, Pay and Auditor Votes
Aug 3, 2026
On August 3, 2026, Compugen Ltd. began distributing its proxy materials for the 2026 annual general meeting scheduled for September 10, 2026, at its offices in Holon, Israel. Shareholders of record as of July 27, 2026, were invited to attend in pe...
Compugen Posts Q2 2026 Results as Key Cancer Immunotherapy Trials Advance
Aug 3, 2026
Compugen reported its second-quarter 2026 results on August 3, highlighting continued clinical and financial progress in its immuno-oncology programs. The company ended June 30 with about $125.3 million in cash and no debt, projecting a runway to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.